Speakers
Speakers taking part in the programme will be listed as we receive their information.
Antonino Spinelli
Antonino Spinelli leads the colon and rectal surgery team in Humanitas Research Hospital, and is Assistant Professor of Surgery at the University of Milan. His team is internationally known for using the most advanced techniques in minimally invasive colorectal surgery. More about Antonino Spinelli…
Aung Ko Win
Aung Ko Win works at the Centre for Epidemiology and Biostatics at the University of Melbourne in Victoria, Australia. He will be speaking on the role of environmental modifiers in the risk of colorectal cancer for Lynch syndrome and the potential of International Mismatch Repair Consortium (IMRC) collaboration. More about Aung Ko Win…
Deborah Alsina
Deborah Alsina is the chief executive of Bowel Cancer UK. She has worked in the not for profit sector in the UK for 25 years. She has worked for a diverse range of non profits during this time in a range of fundraising, international policy and senior management roles. For the five years prior to joining Bowel Cancer UK, she was a successful self-employed consultant specialising in strategy, change management, fundraising and communications. More about Deborah Alsina…
Elisa Scarselli
CSO of Nouscom, a biotech working in novel vaccination strategies for cancer immunotherapy. Elisa has long experience in immunology and molecular biology, including cancer immunotherapy, and in clinical development of viral vectored vaccines. She will be speaking on ‘Development of viral delivery systems for cancer vaccines’. More about Elisa Scarselli…
Finlay Macrae
Lead gastroenterologist in the Familial Cancer Clinic at The Royal Melbourne Hospital. He led the Australian arm of the CAPP2 trial and now the CAPP3 trial of aspirin in Lynch Syndrome, and instigated the merge of mismatch repair variant databases in the InSiGHT MMR database and its Variant Interpretation Committee. More about Finlay Macrae…
Gabriel Capellá
Director of the Hereditary Cancer Program at the Instituto Catalán de Oncología. Main interest is the study of the genetic basis of gastrointestinal cancer focusing in novel technologies for the clinical management of patient at risk of developing GI Cancer. Vice-Director for Research and Innovation, Health Department, Catalan Government. Co-founder of VCN Biosciences. More about Gabriel Capellá…
Gabriela Möslein 
Established the Polyposis Registry at the University of Heidelberg and the Department for Hereditary Tumors, HELIOS Klinikum Wuppertal and University of Witten-Herdecke. She will be speaking about “Surgical Strategies for Pouch Surgery: Can We Improve?”. More about Gabriela Möslein…
Ian Frayling
Helped to establish APC testing in familial polyposis and microsatellite instability testing in Lynch syndrome at the Family Cancer Clinic at St Mark’s Hospital. There he also helped identify the CRAC1 locus (now known to be GREM1). Works on mutation interpretation and systematic testing of incident cancers to identify hereditary cases. More about Ian Frayling…
Ian Tomlinson
Ian Tomlinson works at the University of Oxford. One of his major interests is the identification of colorectal cancer predisposition genes. He has a particular interest in polyp susceptibility, including the Mendelian polyposis syndromes. He will be speaking about PPAP and NAP. More about Ian Tomlinson…
John Burn
Professor of Clinical Genetics, Newcastle University, UK. Consultant Clinical Geneticist in the Northern Genetics Service. Chief Investigator CaPP, the international Cancer Prevention Programme. Director Collaborative Group for Genetics in Healthcare and chair of Department of Health Rare Disorders Databases and Registries Advisory Group. More about John Burn…
John Paul Plazzer
John Paul is the curator of the InSiGHT database, an international database for genetic variants relating to inherited GI cancer, and a member of the InSiGHT Variant Interpretation Committee, which is working to establish a definitive collection of genetic variant classifications. He will be speaking on LOVD and big data management. More about John Paul Plazzer
Magnus von Knebel-Doeberitz
Medical Director of the Department of Applied Tumor Biology at the Institute of Pathology, University Hospital Heidelberg and leads the Clinical Cooperation Unit G105 at the German Cancer Research Centre in Heidelberg. He will be speaking on strategies to develop vaccines against MSI cancers. More about Magnus von Knebel-Doeberitz…
Mark Jenkins
Mark Jenkins is Director of the Centre for Epidemiology & Biostatistics at The University of Melbourne. He will be speaking at Friday’s Registries and Guidelines session. More about Mark Jenkins…
Pål Møller
Clinical geneticist. Runs an outpatient clinical genetic department. Has focused on prospective studies in Norway and internationally for path_BRCA carriers; participated in the European demonstration programme on how to implement BRCA testing clinically. He will be speaking on the prospectively observed penetrance and expressivity of the different path_MMR variants. More about Pål Møller…
Pauline Skarrott
Pauline Skarrott is a retired doctor and trustee of Lynch Syndrome UK, a charity that supports and provides information for people with Lynch syndrome and their families. Pauline will be giving an overview of the charity, now into its second year, and its plans for the future. More about Pauline Skarrott…
Stefan Aretz
Stefan Aretz is a medical geneticist with a long-term interest in familial tumour syndromes, working at the Institute of Human Genetics at the University Hospital Bonn. His main scientific interest is genetic and clinical research in gastrointestinal polyposis syndromes. He will be speaking on MUTYH and MAP. More about Stefan Aretz…
